Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

Novo Nordisk is closing in on a one-two punch it believes could shift the treatment paradigm for obesity with the pick of an amylin/semaglutide combination as its next big therapy in the disease.

The combo is set to enter late-stage development in 2021, on the  heels of clinical data from a cardiovascular outcomes trial of Novo’s semaglutide monotherapy in obesity. The pharma hopes the evidence of the CVOT will persuade physicians of the imperative to treat obesity proactively, and pave the way for the even-greater efficacy the combo could produce. ...